Privia Health Group, Inc.
In the published model solve dated 2026-Q2, anchored at $20.79, Privia Health Group, Inc. (PRVA) is priced for today's economics sustained for ~11.7 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
- The business is capital-light and debt-free, with about $420 million in net cash and no gross debt. That balance sheet, plus a model that adds physicians without buying their practices, is the structural advantage the bull case rests on. - At about $24 the price is rich on every static frame. The market pays roughly 85 times operating income, which implies growth held at a self-funding ceiling for about 16 years. Only the growth-DCF reaches the price; asset, earnings-power, and peer-multiple f
Is PRVA overvalued? See what's priced in →
283 institutional managers reported holding PRVA in 13F filings for the quarter ended 2026-03-31. Together they hold about 92% of the company; the top 10 hold 62%. 43 opened new positions that quarter. Held by BlackRock, FMR (Fidelity), Vanguard Group, among others. On the short side, 3.0M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (2.9 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
PRVA's share count grew 20.8% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at PRVA over the trailing three years: 2024: 7 buys totaling $9.31M. 12 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
PRVA's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | +1.6% | -14.7% |
| 2023-11-04 | +14.3% | -9.5% |
| 2024-02-28 | +9.4% | -17.6% |
| 2024-05-10 | -4.7% | -0.3% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
PRVA's latest 8-K filings: 2026-08-18 (items 5.02, 9.01); 2026-08-06 (items 2.02, 9.01); 2026-07-07 (items 5.02); 2026-05-22 (items 5.07); 2026-05-07 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.